Geron

Geron Debt Growth

The Year-over-Year Debt Growth of Geron (GERN) as of Nov 6, 2026 is -42.86 %. In the previous year, Year-over-Year Debt Growth was 196.87 % — a change of -121.77% (lower).

Debt Growth

-42.86 %

YoY

-121.77%

Last updated:

Year-over-Year Debt Growth of Geron is 2025 -42.86 % . Year-over-Year Debt Growth of Geron was 2024 196.87 % . It decreases by -121.77% lower compared to the previous year.

The Geron Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2021
107.50 USD
Jan 1, 2022
2.81 USD
Jan 1, 2023
60.05 USD
Jan 1, 2024
196.87 USD
Jan 1, 2025
-42.86 USD
The Geron Debt Growth history
YEARDebt GrowthYoY
-42.86 %-121.77%
196.87 %+227.86%
60.05 %+2,035.95%
2.81 %-97.38%
107.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Geron Stock analysis

What does Geron do? Geron Corp is a biopharmaceutical company headquartered in Menlo Park, California, founded in 1990. The company's goal is to develop innovative products and therapies that have the potential to combat serious diseases. Geron Corp specializes in the research of embryonic stem cells. The company is a pioneer in researching technologies for the use of stem cells and has made significant breakthroughs in the field of regenerative medicine. By developing new stem cell therapies, Geron Corp aims to improve the lives of patients with serious conditions such as cancer, Parkinson's disease, and spinal cord injuries. Geron Corp operates various business segments, including oncology, regenerative medicine, and RNA-based therapies. In the field of oncology, the company focuses on developing therapies for the treatment of cancer, particularly solid tumors. One of the most important developments is the drug Imetelstat, which aims to extend the telomeres of cancer cells by inhibiting the activity of telomerase. Imetelstat is currently in various clinical trials and has the potential to revolutionize the treatment of leukemia and other types of cancer. Another important business segment of Geron Corp is regenerative medicine, particularly the research of therapies for repairing spinal cord injuries. The company has made significant breakthroughs in this area and has a promising pipeline of products aimed at repairing damaged nerve cells in the spinal cord and restoring patients' mobility. Geron Corp is also a leading company in the field of RNA-based therapies. RNA-based therapies aim to regulate gene activity to treat diseases. The company has developed various innovative technologies aimed at accelerating and enhancing the development of RNA-based therapies. In recent years, Geron Corp has brought a variety of products to the market, including drugs for the treatment of spinal cord injuries, leukemia, and other types of cancer. The company has also formed partnerships with other leading companies in the biopharmaceutical industry to advance the development and commercialization of products. Overall, Geron Corp has made a significant contribution to the research and development of new technologies and therapies with the potential to improve the lives of millions of people. The company has a promising pipeline of products and is committed to further solidifying its position as a leading company in the biopharmaceutical industry. Geron is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Geron stock

Year-over-Year Debt Growth of Geron is -42.86 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Geron since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Geron historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Geron

All Key Metrics — Geron